Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: A new conjugate vaccine against invasive meningococcal disease

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 85-99

  Hedari, Carine P ^a   Khinkarly, Rima W ^a   Dbaibo, Ghassan S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Coadministration; Immunogenicity; Meningococcal conjugate vaccine; Reactogenicity and safety

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA TOXOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENHIBRIX; MENINGOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; MUTANT PROTEIN; NEISVAC-C; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; QUINOLONE DERIVATIVE; RIFAMPICIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; CHILD HEALTH CARE; CLINICAL TRIAL (TOPIC); CORYNEBACTERIUM DIPHTHERIAE; CROSS REACTION; DRUG CONJUGATION; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG SAFETY; EUROPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INVASIVE MENINGOCOCCAL DISEASE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; UNITED KINGDOM; UNITED STATES; VACCINATION;

EID: 84898483961     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S36243     Document Type: Review

References (107)

1. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467-492.
2. Baltimore RS. Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr Opin Pediatr. 2006;18:58-63.
3. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23(Suppl 12):S274-S279.
4. Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child. 2012;97(11):993-998.
5. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-2):1-28.
6. Tzeng YL, Stephens DS. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2000;2(6):687-700.
7. de Souza AL, van de Beek D, Scheld WM. Meningococcal Disease. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens and Practice. 3rd ed. Edinburgh: W.B. Saunders; 2011:174-183.
8. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, menin-gococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580): 2196-2210.
9. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1-20.
10. Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offt PA, editors. Vaccines. 6th ed. London: W.B. Saunders; 2013:388-418.
11. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853-861.
12. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388.
13. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142-164.
14. Keiser PB, Broderick M. Meningococcal polysaccharide vaccine failure in a patient with C7 defciency and a decreased anti-capsular antibody response. Hum Vaccin Immunother. 2012;8(5):582-586.
15. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev. 2007;31(1):52-63.
16. Papaevangelou V, Spyridis N. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Expert Rev Vaccines. 2012;11(5):523-537.
17. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129(6):1327-1348.
18. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16): 1511-1520.
19. D'Agati VC, Marangoni BA. The Waterhouse-Friderichsen Syndrome. N Engl J Med. 1945;232(1):1-7.
20. Fellick JM, Sills JA, Marzouk O, Hart CA, Cooke RW, Thomson A P. Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch Dis Child. 2001;85(1):6-11.
21. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30 Suppl 2:B3-B9.
22. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningo-coccal disease in college students. Clin Infect Dis. 2001;33(5): 737-739.
23. Kimmel SR. Prevention of Meningococcal Disease. Am Fam Physician. 2005;72:2049-2056.
24. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med. 2006;355(14):1466-1473.
25. Hebert CJ, Hall CM, Odoms LN. Lessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st century. Hum Vaccin Immunother. 2012;8(5):560-568.
26. Jódar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet. 2002;359(9316): 1499-1508.
27. Ramsay M, Kaczmarski E, Rush M, Mallard R, Farrington P, White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev. 1997;7(4): R49-R54.
28. Rouphael NG, Zimmer SM, Stephens DS. Neisseria meningitidis. In: Barrett ADT, Stanberry LR, editors. Vaccines for Biodefense and Emerging and Neglected Diseases. London: Academic Press; 2009:1061-1079.
29. No authors listed. Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88(12):129-136. English, French.
30. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2:B51-B63.
31. Poland GA. Prevention of meningococcal disease: current use of poly-saccharide and conjugate vaccines. Clin Infect Dis. 2010;50 Suppl 2: S45-S53.
32. Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 menin-gococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9(6): 665-671.
33. Borrow R. Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis. 2009;7(4):219-225.
34. Memish ZA, Venkatesh S, Ahmed QA. Travel epidemiology: the Saudi perspective. Int J Antimicrob Agents. 2003;21(2):96-101.
35. Ongoing Struggle with Meningitis W135 in Chile. Available from: http:// healthmap.org/site/diseasedaily/article/ongoing-struggle-meningitis-w135-chile-61813. Accessed June 15, 2013.
36. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657-663.
37. Seward RJ, Towner KJ. Evaluation of a PCR-immunoassay technique for detection of Neisseria meningitidis in cerebrospinal fluid and peripheral blood. J Med Microbiol. 2000;49(5):451-456.
38. MacNeil JR. Chapter 8: Meningococcal Disease; Manual for the Surveillance of Vaccine-Preventable Diseases (5th Edition, 2011) [webpage on the Internet]. Atlanta: Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/vaccines/pubs/ surv-manual/chpt08-mening.html.
39. Joshi VS, Bajaj IB, Survase SA, Singhal RS, Kennedy J F. Meningococcal polysaccharide vaccines: A review. Carbohydr Polym. 2009;75(4):553-565.
40. Girard M P, Preziosi M P, Aguado MT, Kieny MP. A review of vaccine research and development: Meningococcal disease. Vaccine. 2006;24(22):4692-4700.
41. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;27 Suppl 2:B30-B41.
42. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev. 2005;(1): CD001093.
43. Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™). Drugs. 2012;72(18):2407-2430.
44. Shao PL, Chang LY, Hsieh SM, et al. Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease. J Formos Med Assoc. 2009;108(7):539-547.
45. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3-14.
46. Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Drugs Aging. 2013;30(5):309-319.
47. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307-322.
48. No authors listed. Meningococcal vaccines: WHO position paper, Nov 2011. Wkly Epidemiol Rec. 2011;86(47):521-539. English, French.
49. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011;364(24):2293-2304.
50. Wilder-Smith A. Meningococcal disease: Risk for international travellers and vaccine strategies. Travel Med Infect Dis. 2008;6(4):182-186.
51. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50 Suppl 2:S54-S65.
52. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355-357.
53. Kaaijk P, van der Ende A, Luytjes W. Routine vaccination against MenB: Considerations for implementation. Hum Vaccin Immunother. 2013;10(2):1-7.
54. Novartis media releases. Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe [webpage on the Internet]. Basel: Novartis International AG; 2013. Availabe from: http://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtml. Accessed November 1, 2013.
55. A new MenB (meningococcal B) vaccine [webpage on the Internet]. Belfast, Bristol, Dublin, Edinburgh: Meningitis Research Foundation; 2013. Available from: http://www.meningitis.org/menb-vaccine. Accessed November 1, 2013.
56. Agency EM. Bexsero. European public assessment report. Meningococcal group B vaccine (rDNA, component, adsorbed) [webpage on the Internet]. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Summary_for_the_public/human/002333/ WC500137857.pdf. Accessed November 1, 2013.
57. Roderick M, Finn A. Advances towards the prevention of meningococcal B disease: A multidimensional story. J Infect. 2014;68 Suppl 1:S76-S82.
58. Novartis International AG. Bexsero Fact sheet. Basel: Novartis International AG. Available from: http://www.novartisvaccines.com/ downloads/meningococcal-disease/Bexsero_Fact_Sheet.pdf. Accessed November 1, 2013.
59. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16(12): 1810-1815.
60. MenAfriCar Consortium, Ali O, Aseffa A, et al. Meningococcal carriage in the African meningitis belt. Trop Med Int Health. 2013;18(8): 968-978.
61. Frasch CE, Preziosi M P, La Force FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM). Hum Vaccin Immunother. 2012;8(6):715-724.
62. Trotter CL, Yaro S, Njanpop-Lafourcade BM, et al. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PloS One. 2013;8(2):e55486.
63. Centers for Disease Control and Prevention (CDC). Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(50):1022-1024.
64. Novak RT, Kambou JL, Diomandé F V, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12(10):757-764.
65. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis. 2006;6(10):616-617.
66. Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J. 2007;26(5):371-376.
67. Borrow R, Abad R, Trotter C, van der Klis FRM, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31(41):4477-4486.
68. Menitorix - Summary of Product Characteristics [webpage on the Internet]. Uxbridge: GlaxoSmithKline UK; 2005 [updated October 10, 2013]. Available from: http://www.medicines.org.uk/emc/medi-cine/17189/SPC/. Accessed on October 29, 2013.
69. GlaxoSmithKline. MENHIBRIX (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine). Brentford: GlaxoSmithKline plc; 2012. Available from: http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM308577.pdf. Accessed on October 29, 2013.
70. Cramer J P, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25(5):507-517.
71. Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31(11):1173-1183.
72. Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics. 2011;128(6): 1213-1218.
73. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30(6):451-455.
74. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, Jun 2005-Sep 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120-1124.
75. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350-1358.
76. Smith MJ. Meningococcal tetravalent conjugate vaccine. Expert Opin Biol Ther. 2008;8(12):1941-1946.
77. GBS and Menactra Meningococcal Vaccine [webpage on the Internet]. Atlanta: Centers for Disease Control and Prevention (CDC); 2009 [last updated October 9, 2009]. Available from: http://www.cdc.gov/vaccine-safety/vaccines/gbsfactsheet.html. Accessed on October 15, 2013.
78. Novartis AG. MENVEO® [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]. Cambridge: Novartis Vaccines and Diagnostics, Inc.; 2010. Available at: http://www. fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProd-ucts/UCM201349.pdf. Accessed on October 1, 2013.
79. Novartis International AG. Fda Expands Age Indication for Menveo®, First and Only Quadrivalent Meningococcal Vaccine for Infants as Young as 2 Months Of Age. Basel: Novartis International AG; 2013. Available from: http://hugin.info/134323/R/1720709/572916.pdf. Accessed October 1, 2013.
80. Vaccines, Blood and Biologics: Menveo - Approval Letter [webpage on the Internet]. Silver Spring: US Food and Drug Administration; 2013 [last updated September 10, 2013]. Available from: http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm363785.htm. Accessed August 1, 2013.
81. Toy Brown R. ACIP Approves 2014 Child/Adolescent Immunization Schedule. Medscape. Available from: http://www.medscape.com/ viewarticle/813092. Accessed October 23, 2013.
82. Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011;10(1):21-33.
83. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunoge-nicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010;14(10): e868-e875.
84. Nimenrix. European Medicines Agency [webpage on the Internet]. London: European Medicines Agency; 2012 [last updated June 6, 2016]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002226/human_med_001548.jsp&mid=WC0b01ac058001d124. Accessed on November 13, 2013.
85. Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother. 2012;8(7):873-880.
86. Findlow H, Borrow R. Immunogenicity and safety of a meningococ-cal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther. 2013;30(5):431-458.
87. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28(3):744-753.
88. Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012;8(7):866-872.
89. Klein N P, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups a, C, w-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32(7):760-767.
90. Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8(12): 1892-1903.
91. Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine. 2011;29(25): 4274-4284.
92. Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Hum Vaccin Immunother. 2012;8(12): 1882-1891.
93. Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30(4):e56-e62.
94. Dbaibo G, Van der Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profle in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 2012;16(8):e608-e615.
95. Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year- old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013;172(5):601-612.
96. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009;27(1):161-168.
97. Bermal N, Huang LM, Dubey A P, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7(2): 239-247.
98. Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.
99. Østergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2013;17(3): e173-e176.
100. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent menin-gococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30(3):e41-e48.
101. Lupisan S, Limkittikul K, Sosa N, et al. Meningococcal poly-saccharide A O-acetylation level does not impact the immu-nogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT): results from a randomized, controlled Phase III study in healthy adults aged 18-25 years. Clin Vaccine Immunol. 2013;20(10):1499-1507.
102. McVernon J, Nolan T, Richmond P, et al. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. Pediatr Infect Dis J. 2012;31(1):e15-e23.
103. Østergaard L, Silfverdal SA, Berglund J, et al. A tetravalent menin-gococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012;30(4):774-783.
104. Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal infuenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8(7):881-887.
105. Ruiz-Palacios GM, Huang LM, Lin TY, et al. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenza protein D conjugate vaccine coadministered with the tet-ravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J. 2013;32(1):62-71.
106. Knuf M, Pantazi-Chatzikonstantinou A, Pfetschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29(25):4264-4273.
107. Vaccination for Meningococcal disease [webpage on the Internet]. London: Public Health England; 2013 [last updated July 12, 2013]. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/MeningococcalDisease/GeneralInformation/meninvaccinationfactsheet/. Accessed October 1, 2013.